Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.

Published byHarjanti Cahyadi Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells."— Presentation transcript:

1 Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells
APCs from laquinimod-treated mice inhibit differentiation of Tfh cells Splenic CD90.2− cells from mice treated in vivo with laquinimod or vehicle were used as APCs in a reciprocal manner to stimulate naive (CD4+CD44−CD62L+) T cells from MOG p35-55 T cell receptor transgenic mice (2D2) treated with laquinimod or vehicle. APCs and T cells were cultured with MOG p35-55 in Tfh-polarizing conditions (IL-6, IL-21, anti-IL-4, -IL-12, -IFN-γ and -TGF-β antibodies) from the start of culture. Flow cytometry analysis for expression of Tfh cell markers was performed after 3 days of culture. APC = antigen-presenting cell; IFN-γ = interferon γ; IL = interleukin; LAQ = laquinimod; MOG = myelin oligodendrocyte glycoprotein; PD-1 = programmed cell death protein 1; Tfh = T follicular helper; TGF-β = transforming growth factor β; Veh = vehicle. Michel Varrin-Doyer et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e272 © 2016 American Academy of Neurology

Download ppt "Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells."

Similar presentations

Computational Modelling of Circuits Homework assignment, group 2

Computational Modelling of Circuits Homework assignment, group 2
Loss of Extracellular Superoxide Dismutase Induces Severe IL-23-Mediated Skin Inflammation in Mice  Yun Sang Lee, In-Su Cheon, Byung-Hak Kim, Myung-Ja.

Loss of Extracellular Superoxide Dismutase Induces Severe IL-23-Mediated Skin Inflammation in Mice  Yun Sang Lee, In-Su Cheon, Byung-Hak Kim, Myung-Ja.
Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.

Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.

Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.

Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.
by Éric Aubin, Réal Lemieux, and Renée Bazin

by Éric Aubin, Réal Lemieux, and Renée Bazin
Figure 1 Percent positivity by clinical feature Overall, 6

Figure 1 Percent positivity by clinical feature Overall, 6
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Unraveling the Pros and Cons of Interferon-γ Gene Regulation

Unraveling the Pros and Cons of Interferon-γ Gene Regulation
Figure 3 Differentiation and functional control of T-cell subsets

Figure 3 Differentiation and functional control of T-cell subsets
Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.

Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.
Volume 140, Issue 7, Pages (June 2011)

Volume 140, Issue 7, Pages (June 2011)
Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.

Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.
Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.
Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.

Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.
Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents.

Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents.
Figure 2 Binding of the patient's IgG to Purkinje cells is inhibited by pretreatment of rat tissue with anti-VGCC antibodies, confirming specificity of.

Figure 2 Binding of the patient's IgG to Purkinje cells is inhibited by pretreatment of rat tissue with anti-VGCC antibodies, confirming specificity of.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.

Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.
Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Similar presentations

Ads by Google